Brooke Kwai

Brooke Kwai is a Research Fellow in Medicinal Chemistry at Monash University, actively engaged in biochemical and pharmaceutical research targeting Mycobacterium tuberculosis. Her work focuses on key metabolic enzymes such as isocitrate lyase and their role in bacterial persistence and drug resistance.

Research Interests: Her primary research areas include medicinal chemistry, enzyme inhibition, tuberculosis therapeutics, and metabolic pathway disruption in pathogens. She employs biophysical and biochemical techniques to study protein-ligand interactions and validate drug targets.

The analysis of her recent publications reveals a consistent focus on targeting the glyoxylate shunt in M. tuberculosis, particularly through isocitrate lyase modulation via inhibitors, covalent modifiers like itaconate, and allosteric regulators such as Acetyl-CoA. These studies contribute significantly to the development of novel anti-tuberculosis agents, especially for latent infection.

Scientific Recognition:

• Her research has been cited over 40 times in Scopus for multiple works.
• Featured in 3 Wikipedia pages and referenced by 3 news outlets.
• Blogged about and widely shared on X (formerly Twitter) by researchers and institutions.
• High readership on Mendeley, with up to 82 readers for a single article.

Collaboration and Advising: Brooke Kwai collaborates extensively with researchers including G. Bashiri, I.K.H. Leung, R.P. Bhusal, and J. Sperry. While no formal advisees are listed, her role suggests active participation in a research team contributing to training and project supervision. There is no mention of independent grants, but her consistent output implies involvement in funded projects.

Laboratory and Network: She operates within a research group focused on structural and medicinal chemistry at Monash University, utilizing techniques such as NMR, thermal shift assays, and enzyme kinetics to evaluate potential therapeutics for tuberculosis.